Enzymatica AB

Quotes

ColdZyme is the future of cold relief. By breaking the viral cycle at the first signs of symptoms, the product helps cut illness duration in half and speeds up recovery.

Sana Alajmovic

We offer a unique, evidence-based alternative in a market dominated by outdated products. ColdZyme reduces viral load by 94 percent, helping you avoid putting your life on hold.

Sana Alajmovic

My focus is to lead Enzymatica into its next phase of growth. ColdZyme is a consumer favorite with clinically proven efficacy – we have the potential to become a global leader.

Sana Alajmovic

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Year-end report 2024: Strong performance in core markets – preparing for international growth

Tue, Feb 18, 2025 08:30 CET

Fourth quarter January-December · Net sales · Net sales reached SEK 45.6 millionreached SEK 17.2 (50.9).million (15.8). · The operating result totaled SEK -52.1 · The operating million (-48.1).result totaled SEK · Earnings per share, basic and diluted,-13.7 million ( were-13.8). SEK -0.28 (-0.30). · Earnings per · Cash flow from operating activities forshare, basic and the period totaled SEK -60.5 million (diluted, were SEK -40.3).-0.05 (-0.09). · Net cash totaled SEK 73.0 million ( · Cash flow

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

Quotes

Year-end report 2024: Strong performance in core markets – preparing for international growth

Subscribe